Primary Outcomes From the Phase 3 Study of Tafasitamab Plus Lenalidomide and R-CHOP for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (frontMIND) (SOHO 2026) - Sep 1, 2026 - Abstract #ABCL-489; Location: LEVEL 3, HALL B3; "Tafa-Len-R-CHOP resulted in a significant 25% reduction in risk of disease progression or death vs RCHOP, without affecting CD19 expression in relapse biopsies. TEAEs were manageable and consistent with the expected safety profile. Tafa-Len-R-CHOP represents a new first-line standard-ofcare option for patients with high-risk DLBCL or HGBL, regardless of COO molecular subtype."
Clinical • P3 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • CD19
|
|
Jason Westin 1; Georg Lenz 2; Marek Trnený 3; John M Burke 4; Grzegorz S Nowakowski 5; Christopher P Fox 6; Annalisa Chiappella 7; Johannes Duell 8; Chan Y Cheah 9; Joseph Z Ye 10; Priscilla B Caguioa 11; David Belada 12; Sung Yong Oh 13; Sandy Amorim 14; Andreas Rosenwald 15; Roberto Chiarle 16; Philomena Colucci 17; Sonia Ioannidis 18; Lulu Cheng 17; Umberto Vitolo 19
|